Prot #CC-10004-AD-001: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Atopic Dermatitis

  • Gordon, Kenneth B (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/15/1410/15/17

Funding

  • PPD Development (Prot #CC-10004-AD-001)
  • Celgene Corporation (Prot #CC-10004-AD-001)